Skip to content
2000
image of Navigating the COVID-19 Treatment Landscape: Efficacy and Side-Effects of Current Therapies against SARS-CoV-2

Abstract

Coronavirus Disease 2019 (COVID-19), caused by the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China. Designated as an epidemic by the World Health Organization (WHO) on January 30, 2020, the virus quickly escalated to a global emergency, officially declared a pandemic in March 2020. With over 6 million recorded deaths and more than 200 identified symptoms in diverse individuals, the impact of COVID-19 is substantial. COVID-19 poses a greater risk to individuals with advanced HIV, while those with well-managed HIV are not at increased risk. Although COVID-19 vaccines are generally effective for people with HIV, some may experience reduced vaccine effectiveness and breakthrough infections due to suboptimal immune responses. Long COVID, affecting at least 65 million individuals, adds a layer of complexity. The virus's rapid mutation has led to diverse symptomatology, prompting adjustments in treatment guidelines. This review comprehensively examines repurposed antiviral drug candidates against COVID-19, explores immune responses across different age groups, delves into the mechanisms of COVID-19 vaccines, and discusses potential immunosuppressants. Additionally, the focus extends to Intravenous Immunoglobulin (IVIG), steroids, and anti-cytokine therapy as promising avenues to address cytokine release syndrome (CRS), a critical condition in COVID-19 patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X338375250414114957
2025-04-28
2025-09-05

  • From This Site

    /content/journals/chr/10.2174/011570162X338375250414114957
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Wang D. Hu B. Hu C. Zhu F. Liu X. Zhang J. Wang B. Xiang H. Cheng Z. Xiong Y. Zhao Y. Li Y. Wang X. Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020 323 11 1061 1069 10.1001/jama.2020.1585 32031570
    [Google Scholar]
  2. Davis H.E. Assaf G.S. McCorkell L. Wei H. Low R.J. Re’em Y. Redfield S. Austin J.P. Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021 38 101019 10.1016/j.eclinm.2021.101019 34308300
    [Google Scholar]
  3. Weiss S.R. Leibowitz J.L. Coronavirus pathogenesis. Adv. Virus Res. 2011 81 85 164 10.1016/B978‑0‑12‑385885‑6.00009‑2 22094080
    [Google Scholar]
  4. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 2016 3 1 237 261 10.1146/annurev‑virology‑110615‑042301 27578435
    [Google Scholar]
  5. Tang Q. Song Y. Shi M. Cheng Y. Zhang W. Xia X.Q. Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition. Sci. Rep. 2015 5 1 17155 10.1038/srep17155 26607834
    [Google Scholar]
  6. Su S. Wong G. Shi W. Liu J. Lai A.C.K. Zhou J. Liu W. Bi Y. Gao G.F. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016 24 6 490 502 10.1016/j.tim.2016.03.003 27012512
    [Google Scholar]
  7. Malik Y.S. Sircar S. Bhat S. Sharun K. Dhama K. Dadar M. Tiwari R. Chaicumpa W. Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments. Vet. Q. 2020 40 1 68 76 10.1080/01652176.2020.1727993 32036774
    [Google Scholar]
  8. Hu B. Guo H. Zhou P. Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021 19 3 141 154 10.1038/s41579‑020‑00459‑7 33024307
    [Google Scholar]
  9. Beyerstedt S. Casaro E.B. Rangel É.B. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021 40 5 905 919 10.1007/s10096‑020‑04138‑6 33389262
    [Google Scholar]
  10. He S. Waheed A.A. Hetrick B. Dabbagh D. Akhrymuk I.V. Kehn-Hall K. Freed E.O. Wu Y. PSGL-1 inhibits the incorporation of SARS-CoV and SARS-CoV-2 spike glycoproteins into pseudovirions and impairs pseudovirus attachment and infectivity. Viruses 2020 13 1 46 10.3390/v13010046 33396594
    [Google Scholar]
  11. Kokic G. Hillen H.S. Tegunov D. Dienemann C. Seitz F. Schmitzova J. Farnung L. Siewert A. Höbartner C. Cramer P. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 2021 12 1 279 10.1038/s41467‑020‑20542‑0 33436624
    [Google Scholar]
  12. Metwally K. Abo-Dya N.E. Alahmdi M.I. Albalawi M.Z. Yahya G. Aljoundi A. Salifu E.Y. Elamin G. Ibrahim M.A.A. Sayed Y. Fanucchi S. Soliman M.E.S. The unusual architecture of RNA-dependent RNA Polymerase (RdRp)’s catalytic chamber provides a potential strategy for combination therapy against COVID-19. Molecules 2023 28 6 2806 10.3390/molecules28062806 36985777
    [Google Scholar]
  13. Wu Z. McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA 2020 323 13 1239 1242 10.1001/jama.2020.2648 32091533
    [Google Scholar]
  14. Huang C. Wang Y. Li X. Ren L. Zhao J. Hu Y. Zhang L. Fan G. Xu J. Gu X. Cheng Z. Yu T. Xia J. Wei Y. Wu W. Xie X. Yin W. Li H. Liu M. Xiao Y. Gao H. Guo L. Xie J. Wang G. Jiang R. Gao Z. Jin Q. Wang J. Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 395 10223 497 506 10.1016/S0140‑6736(20)30183‑5 31986264
    [Google Scholar]
  15. Guan W. Ni Z. Hu Y. Liang W. Ou C. He J. Liu L. Shan H. Lei C. Hui D.S.C. Du B. Li L. Zeng G. Yuen K.Y. Chen R. Tang C. Wang T. Chen P. Xiang J. Li S. Wang J. Liang Z. Peng Y. Wei L. Liu Y. Hu Y. Peng P. Wang J. Liu J. Chen Z. Li G. Zheng Z. Qiu S. Luo J. Ye C. Zhu S. Zhong N. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020 382 18 1708 1720 10.1056/NEJMoa2002032 32109013
    [Google Scholar]
  16. Lu X. Zhang L. Du H. Zhang J. Li Y.Y. Qu J. Zhang W. Wang Y. Bao S. Li Y. Wu C. Liu H. Liu D. Shao J. Peng X. Yang Y. Liu Z. Xiang Y. Zhang F. Silva R.M. Pinkerton K.E. Shen K. Xiao H. Xu S. Wong G.W.K. SARS-CoV-2 infection in children. N. Engl. J. Med. 2020 382 17 1663 1665 10.1056/NEJMc2005073 32187458
    [Google Scholar]
  17. Chen N. Zhou M. Dong X. Qu J. Gong F. Han Y. Qiu Y. Wang J. Liu Y. Wei Y. Xia J. Yu T. Zhang X. Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020 395 10223 507 513 10.1016/S0140‑6736(20)30211‑7 32007143
    [Google Scholar]
  18. Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat. Med. 2021 27 1 28 33 10.1038/s41591‑020‑01202‑8 33442016
    [Google Scholar]
  19. Peluso M.J. Deeks S.G. Mechanisms of long COVID and the path toward therapeutics. Cell 2024 187 20 5500 5529 10.1016/j.cell.2024.07.054 39326415
    [Google Scholar]
  20. Punekar M. Kshirsagar M. Tellapragada C. Patil K. Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system. Microb. Pathog. 2022 168 105608 10.1016/j.micpath.2022.105608 35654381
    [Google Scholar]
  21. Yin W. Mao C. Luan X. Shen D.D. Shen Q. Su H. Wang X. Zhou F. Zhao W. Gao M. Chang S. Xie Y.C. Tian G. Jiang H.W. Tao S.C. Shen J. Jiang Y. Jiang H. Xu Y. Zhang S. Zhang Y. Xu H.E. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020 368 6498 1499 1504 10.1126/science.abc1560 32358203
    [Google Scholar]
  22. Hashemian S.M. Farhadi T. Velayati A.A. A review on favipiravir: The properties, function, and usefulness to treat COVID-19. Expert Rev. Anti Infect. Ther. 2021 19 8 1029 1037 10.1080/14787210.2021.1866545 33372567
    [Google Scholar]
  23. Vansant G. Chen H.C. Zorita E. Trejbalová K. Miklík D. Filion G. Debyser Z. The chromatin landscape at the HIV-1 provirus integration site determines viral expression. Nucleic Acids Res. 2020 48 14 7801 7817 10.1093/nar/gkaa536 32597987
    [Google Scholar]
  24. Upreti S. Samant M. A review on immunological responses to SARS-CoV-2 and various COVID-19 Vaccine regimens. Pharm. Res. 2022 39 9 2119 2134 10.1007/s11095‑022‑03323‑w 35773445
    [Google Scholar]
  25. Bajaj V. Gadi N. Spihlman A.P. Wu S.C. Choi C.H. Moulton V.R. Aging, immunity, and COVID-19: How age influences the host immune response to coronavirus infections? Front. Physiol. 2021 11 571416 10.3389/fphys.2020.571416 33510644
    [Google Scholar]
  26. Dabbagh D. He S. Hetrick B. Chilin L. Andalibi A. Wu Y. Identification of the SHREK family of proteins as broad-spectrum host antiviral factors. Viruses 2021 13 5 832 10.3390/v13050832 34064525
    [Google Scholar]
  27. Höft M.A. Burgers W.A. Riou C. The immune response to SARS-CoV-2 in people with HIV. Cell. Mol. Immunol. 2023 21 2 184 196 10.1038/s41423‑023‑01087‑w 37821620
    [Google Scholar]
  28. Purohit D. Saini M. Pathak N. Verma R. Kaushik D. Katiyar P. Jalwal P. Pandey P. COVID-19 ‘the pandemic’: An update on the present status of the outbreak and possible treatment options. Biomed. Pharmacol. J. 2020 13 4 1791 1807 10.13005/bpj/2054
    [Google Scholar]
  29. Jiang Y. Yin W. Xu H.E. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Biochem. Biophys. Res. Commun. 2021 538 47 53 10.1016/j.bbrc.2020.08.116 32943188
    [Google Scholar]
  30. Jorgensen S.C.J. Kebriaei R. Dresser L.D. Remdesivir: Review of pharmacology, pre‐clinical data, and emerging clinical experience for COVID‐19. Pharmacotherapy 2020 40 7 659 671 10.1002/phar.2429 32446287
    [Google Scholar]
  31. Wang Y. Zhang D. Du G. Du R. Zhao J. Jin Y. Fu S. Gao L. Cheng Z. Lu Q. Hu Y. Luo G. Wang K. Lu Y. Li H. Wang S. Ruan S. Yang C. Mei C. Wang Y. Ding D. Wu F. Tang X. Ye X. Ye Y. Liu B. Yang J. Yin W. Wang A. Fan G. Zhou F. Liu Z. Gu X. Xu J. Shang L. Zhang Y. Cao L. Guo T. Wan Y. Qin H. Jiang Y. Jaki T. Hayden F.G. Horby P.W. Cao B. Wang C. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020 395 10236 1569 1578 10.1016/S0140‑6736(20)31022‑9 32423584
    [Google Scholar]
  32. Gandhi S. Klein J. Robertson A.J. Peña-Hernández M.A. Lin M.J. Roychoudhury P. Lu P. Fournier J. Ferguson D. Mohamed Bakhash S.A.K. Catherine Muenker M. Srivathsan A. Wunder E.A. Jr Kerantzas N. Wang W. Lindenbach B. Pyle A. Wilen C.B. Ogbuagu O. Greninger A.L. Iwasaki A. Schulz W.L. Ko A.I. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report. Nat. Commun. 2022 13 1 1547 10.1038/s41467‑022‑29104‑y 35301314
    [Google Scholar]
  33. Peng Q. Peng R. Yuan B. Wang M. Zhao J. Fu L. Qi J. Shi Y. Structural basis of SARS-CoV-2 polymerase inhibition by Favipiravir. Innovation 2021 2 1 100080 10.1016/j.xinn.2021.100080 33521757
    [Google Scholar]
  34. Furuta Y. Komeno T. Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 2017 93 7 449 463 10.2183/pjab.93.027 28769016
    [Google Scholar]
  35. Ghasemnejad-Berenji M. Pashapour S. Favipiravir and COVID-19: A Simplified Summary. Drug Res. (Stuttg.) 2021 71 3 166 170 10.1055/a‑1296‑7935 33176367
    [Google Scholar]
  36. Sada M. Saraya T. Ishii H. Okayama K. Hayashi Y. Tsugawa T. Nishina A. Murakami K. Kuroda M. Ryo A. Kimura H. Detailed molecular interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza virus polymerases in silico. Microorganisms 2020 8 10 1610 10.3390/microorganisms8101610 33092045
    [Google Scholar]
  37. Batiha G.E.S. Alexiou A. Moubarak M. Shaheen H.M. Zakariya A.M. Usman I.M. Rauf A. Adhikari A. Dey A. Hetta H.F. Al-Gareeb A.I. Al-kuraishy H.M. Favipiravir in SARS-CoV-2 infection: Is it worth it? Comb. Chem. High Throughput Screen. 2022 25 14 2413 2428 10.2174/1386207325666220414111840 35430987
    [Google Scholar]
  38. Verdugo-Paiva F. Izcovich A. Ragusa M. Rada G. Lopinavir/ritonavir for COVID-19: A living systematic review. Medwave 2020 20 6 e7966 10.5867/medwave.2020.06.7966 32678815
    [Google Scholar]
  39. Amani B. Khanijahani A. Amani B. Hashemi P. Lopinavir/Ritonavir for COVID-19: A systematic review and meta-analysis. J. Pharm. Pharm. Sci. 2021 24 246 257 10.18433/jpps31668 34048671
    [Google Scholar]
  40. Horby P.W. Mafham M. Bell J.L. Linsell L. Staplin N. Emberson J. Palfreeman A. Raw J. Elmahi E. Prudon B. Green C. Carley S. Chadwick D. Davies M. Wise M.P. Baillie J.K. Chappell L.C. Faust S.N. Jaki T. Jefferey K. Lim W.S. Montgomery A. Rowan K. Juszczak E. Haynes R. Landray M.J. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (recovery): A randomised, controlled, open-label, platform trial. Lancet 2020 396 10259 1345 1352 10.1016/S0140‑6736(20)32013‑4 33031764
    [Google Scholar]
  41. Cortegiani A. Ingoglia G. Ippolito M. Giarratano A. Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care 2020 57 279 283 10.1016/j.jcrc.2020.03.005 32173110
    [Google Scholar]
  42. Yao X. Ye F. Zhang M. Cui C. Huang B. Niu P. Liu X. Zhao L. Dong E. Song C. Zhan S. Lu R. Li H. Tan W. Liu D. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 2020 71 15 732 739 10.1093/cid/ciaa237 32150618
    [Google Scholar]
  43. Boulware D.R. Pullen M.F. Bangdiwala A.S. Pastick K.A. Lofgren S.M. Okafor E.C. Skipper C.P. Nascene A.A. Nicol M.R. Abassi M. Engen N.W. Cheng M.P. LaBar D. Lother S.A. MacKenzie L.J. Drobot G. Marten N. Zarychanski R. Kelly L.E. Schwartz I.S. McDonald E.G. Rajasingham R. Lee T.C. Hullsiek K.H. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N. Engl. J. Med. 2020 383 6 517 525 10.1056/NEJMoa2016638 32492293
    [Google Scholar]
  44. Wang X. Cao R. Zhang H. Liu J. Xu M. Hu H. Li Y. Zhao L. Li W. Sun X. Yang X. Shi Z. Deng F. Hu Z. Zhong W. Wang M. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020 6 1 28 10.1038/s41421‑020‑0169‑8 32373347
    [Google Scholar]
  45. Blaising J. Polyak S.J. Pécheur E.I. Arbidol as a broad-spectrum antiviral: An update. Antiviral Res. 2014 107 84 94 10.1016/j.antiviral.2014.04.006 24769245
    [Google Scholar]
  46. Leneva I. Kartashova N. Poromov A. Gracheva A. Korchevaya E. Glubokova E. Borisova O. Shtro A. Loginova S. Shchukina V. Khamitov R. Faizuloev E. Antiviral activity of umifenovir in vitro against a broad spectrum of coronaviruses, including the novel SARS-CoV-2 virus. Viruses 2021 13 8 1665 10.3390/v13081665 34452529
    [Google Scholar]
  47. Vegivinti C.T.R. Pederson J.M. Saravu K. Gupta N. Evanson K.W. Kamrowski S. Schmidt M. Barrett A. Trent H. Dibas M. Reierson N.L. Mikoff N. Pisipati S. Joseph B.A. Selvan P.T. Dmytriw A.A. Pulakurthi Y.S. Keesari P.R. Sriram V. Chittajallu S. Brinjikji W. Katamreddy R.R. Chibbar R. Davis A.R. Malpe M. Mishra H.K. Kallmes K.M. Hassan A.E. Efficacy of convalescent plasma therapy for COVID‐19: A systematic review and meta‐analysis. J. Clin. Apher. 2021 36 3 470 482 10.1002/jca.21881 33544910
    [Google Scholar]
  48. Liu R. Mangal R. Stead T.S. Barbera A.R. Ganti L. Use of Casirivimab and Imdevimab for the treatment of COVID-19. Cureus 2022 14 8 e27766 10.7759/cureus.27766 36106219
    [Google Scholar]
  49. Gupta A. Gonzalez-Rojas Y. Juarez E. Crespo Casal M. Moya J. Falci D.R. Sarkis E. Solis J. Zheng H. Scott N. Cathcart A.L. Hebner C.M. Sager J. Mogalian E. Tipple C. Peppercorn A. Alexander E. Pang P.S. Free A. Brinson C. Aldinger M. Shapiro A.E. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody Sotrovimab. N. Engl. J. Med. 2021 385 21 1941 1950 10.1056/NEJMoa2107934 34706189
    [Google Scholar]
  50. Nguyen Y Flahault A Chavarot N Melenotte C Cheminant M Deschamps P Pre-exposure prophylaxis with Tixagevimab and Cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients. Clin Microbiol Infect. 2022 28 10.1016/j.cmi.2022.07.015
    [Google Scholar]
  51. Chew K.W. Moser C. Daar E.S. Wohl D.A. Li J.Z. Coombs R.W. Ritz J. Giganti M. Javan A.C. Li Y. Choudhary M.C. Deo R. Malvestutto C. Klekotka P. Price K. Nirula A. Fischer W. Bala V. Ribeiro R.M. Perelson A.S. Fletcher C.V. Eron J.J. Currier J.S. Hughes M.D. Smith D.M. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat. Commun. 2022 13 1 4931 10.1038/s41467‑022‑32551‑2 35995785
    [Google Scholar]
  52. Hannula L. Kuivanen S. Lasham J. Kant R. Kareinen L. Bogacheva M. Strandin T. Sironen T. Hepojoki J. Sharma V. Saviranta P. Kipar A. Vapalahti O. Huiskonen J.T. Rissanen I. Nanobody engineering for SARS-CoV-2 neutralization and detection. Microbiol. Spectr. 2024 12 4 e04199-22 10.1128/spectrum.04199‑22 38363137
    [Google Scholar]
  53. Patel V.K. Shirbhate E. Patel P. Veerasamy R. Sharma P.C. Rajak H. Corticosteroids for treatment of COVID-19: Effect, evidence, expectation and extent. Beni. Suef Univ. J. Basic Appl. Sci. 2021 10 1 78 10.1186/s43088‑021‑00165‑0 34751250
    [Google Scholar]
  54. Horby P. Lim W.S. Emberson J.R. Mafham M. Bell J.L. Linsell L. Staplin N. Brightling C. Ustianowski A. Elmahi E. Prudon B. Green C. Felton T. Chadwick D. Rege K. Fegan C. Chappell L.C. Faust S.N. Jaki T. Jeffery K. Montgomery A. Rowan K. Juszczak E. Baillie J.K. Haynes R. Landray M.J. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021 384 8 693 704 10.1056/NEJMoa2021436 32678530
    [Google Scholar]
  55. Marconi V.C. Ramanan A.V. de Bono S. Kartman C.E. Krishnan V. Liao R. Piruzeli M.L.B. Goldman J.D. Alatorre-Alexander J. de Cassia Pellegrini R. Estrada V. Som M. Cardoso A. Chakladar S. Crowe B. Reis P. Zhang X. Adams D.H. Ely E.W. Ahn M-Y. Akasbi M. Alatorre-Alexander J. Altclas J.D. Ariel F. Ariza H.A. Atkar C. Bertetti A. Bhattacharya M. Briones M.L. Budhraja A. Burza A. Camacho Ortiz A. Caricchio R. Casas M. Cevoli Recio V. Choi W.S. Cohen E. Comulada-Rivera A. Cook P. Cornejo Juarez D.P. Daniel C. Degrecci Relvas L.F. Dominguez Cherit J.G. Ellerin T. Enikeev D. Erico Tanni Minamoto S. Estrada V. Fiss E. Furuichi M. Giovanni Luz K. Goldman J.D. Gonzalez O. Gordeev I. Gruenewald T. Hamamoto Sato V.A. Heo E.Y. Heo J.Y. Hermida M. Hirai Y. Hutchinson D. Iastrebner C. Ioachimescu O. Jain M. Juliani Souza Lima M.P. Khan A. Kremer A.E. Lawrie T. MacElwee M. Madhani-Lovely F. Malhotra V. Martínez Resendez M.F. McKinnell J. Milligan P. Minelli C. Moran Rodriguez M.A. Parody M.L. Paulin P. Pellegrini R.C. Pemu P. Procopio Carvalho A.C. Puoti M. Purow J. Ramesh M. Rea Neto A. Rea Neto A. Robinson P. Rodrigues C. Rojas Velasco G. Saraiva J.F.K. Scheinberg M. Schreiber S. Scublinsky D. Sevciovic Grumach A. Shawa I. Simon Campos J. Sofat N. Som M. Spinner C.D. Sprinz E. Stienecker R. Suarez J. Tachikawa N. Tahir H. Tiffany B. Vishnevsky A. Westheimer Cavalcante A. Zirpe K. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 2021 9 12 1407 1418 10.1016/S2213‑2600(21)00331‑3 34480861
    [Google Scholar]
  56. Sivapalasingam S. Lederer D.J. Bhore R. Hajizadeh N. Criner G. Hosain R. Mahmood A. Giannelou A. Somersan-Karakaya S. O’Brien M.P. Boyapati A. Parrino J. Musser B.J. Labriola-Tompkins E. Ramesh D. Purcell L.A. Gulabani D. Kampman W. Waldron A. Ng Gong M. Saggar S. Sperber S.J. Menon V. Stein D.K. Sobieszczyk M.E. Park W. Aberg J.A. Brown S.M. Kosmicki J.A. Horowitz J.E. Ferreira M.A. Baras A. Kowal B. Thomas DiCioccio A. Akinlade B. Nivens M.C. Braunstein N. Herman G.A. Yancopoulos G.D. Weinreich D.M. Efficacy and safety of sarilumab in hospitalized patients with coronavirus disease 2019: A randomized clinical trial. Clin. Infect. Dis. 2022 75 1 e380 e388 10.1093/cid/ciac153 35219277
    [Google Scholar]
  57. Fanlo P. Gracia-Tello B.C. Fonseca Aizpuru E. Álvarez-Troncoso J. Gonzalez A. Prieto-González S. Freire M. Argibay A.B. Pallarés L. Todolí J.A. Pérez M. Buján-Rivas S. Ibáñez B. Arnáez R. Huarte E. Sanchez J. Zabalza E. Garcia-Rey R. Gonzalo M. Diez-Galán L. de la Rica-Escuín M. Martinez-Lostao L. Marín Ballvé A. Taboada-Martínez M.L. Pampín-Sánchez R. Helguera-Amézua C. Fernández-Madera-Martínez R. García-Coya E. Álvarez-Suarez A.M. Robles Á. Noblejas A. Soto C. Martínez E. Arnalich F. Arévalo C. López-Rodríguez A. Cobeta P. Hidalgo F. Diz S. González P. Bara N. Fabregate M. Jiménez J. Zhilina S. Pellicer-Ariño M. Rodríguez -Núñez O. Ribot -Grabalosa J. Costafreda-Mas M. Tomé-Pérez A. Hospital-Vidal T. Ladino-Vázquez A. Morancho-Sesé A. Salazar-Rustarazo A. Gabara-Xancó C. Gonzalez -Quintela A. Sopeña B. Alende -Sixto R. Esteban H. Rodriguez-Nuñez N. Andrade-Piña A.H. Sanchidrian-Chapinal M.Á. Varela P. Taboada M. Maure-Noia B. López-Domínguez A. Filloy-Mato C. Gimena-Reyes B. Samartín-Ucha M. Vázquez-Triñanes C. Fernández-Martín J. Paradela-Carreiro A. Regueira-Arcay A.M. Esteban-Marcos E. Martin-Pena L. Fernández-Navarro J.A. Abdilla-Bonias N. Mestre-Torres J. Marques-Soares J.R. Pardos-Gea J. Efficacy and safety of Anakinra plus standard of care for patients with severe COVID-19. JAMA Netw. Open 2023 6 4 e237243 10.1001/jamanetworkopen.2023.7243 37027155
    [Google Scholar]
  58. Razumikhin M. Smolyanova T. Nikolaeva A. Orlova E. Ivanov A. Belyakova O. Vyaznikova T. Selezneva N. Perevozchikov A. Sokolova A. Zubkova N. Efimova I. Dolzhikova I. Logunov D. Sakanjan E. Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma. Immunotherapy 2022 14 14 1133 1147 10.2217/imt‑2022‑0015 35892311
    [Google Scholar]
  59. Hou X. Tian L. Zhou L. Jia X. Kong L. Xue Y. Hao H. Meng X. Zhang F. Dong X. Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: A single-center retrospective cohort study. Virol. J. 2021 18 1 101 10.1186/s12985‑021‑01575‑3 34020680
    [Google Scholar]
  60. Oliver M.A. Davis X.D. Bohannon J.K. TGFβ macrophage reprogramming: A new dimension of macrophage plasticity. J. Leukoc. Biol. 2024 115 3 411 414 10.1093/jleuko/qiae001 38197509
    [Google Scholar]
  61. Shu L. Niu C. Li R. Huang T. Wang Y. Huang M. Ji N. Zheng Y. Chen X. Shi L. Wu M. Deng K. Wei J. Wang X. Cao Y. Yan J. Feng G. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res. Ther. 2020 11 1 361 10.1186/s13287‑020‑01875‑5 32811531
    [Google Scholar]
  62. Lanzoni G. Linetsky E. Correa D. Messinger Cayetano S. Alvarez R.A. Kouroupis D. Alvarez Gil A. Poggioli R. Ruiz P. Marttos A.C. Hirani K. Bell C.A. Kusack H. Rafkin L. Baidal D. Pastewski A. Gawri K. Leñero C. Mantero A.M.A. Metalonis S.W. Wang X. Roque L. Masters B. Kenyon N.S. Ginzburg E. Xu X. Tan J. Caplan A.I. Glassberg M.K. Alejandro R. Ricordi C. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl. Med. 2021 10 5 660 673 10.1002/sctm.20‑0472 33400390
    [Google Scholar]
  63. Reino-Gelardo S. Palop-Cervera M. Aparisi-Valero N. Espinosa-San Miguel I. Lozano-Rodríguez N. Llop-Furquet G. Sanchis-Artero L. Cortés-Castell E. Rizo-Baeza M. Cortés-Rizo X. Effect of an immune-boosting, antioxidant and anti-inflammatory food supplement in hospitalized COVID-19 patients: A prospective randomized pilot study. Nutrients 2023 15 7 1736 10.3390/nu15071736 37049576
    [Google Scholar]
  64. Villasis-Keever M.A. López-Alarcón M.G. Miranda-Novales G. Zurita-Cruz J.N. Barrada-Vázquez A.S. González-Ibarra J. Martínez-Reyes M. Grajales-Muñiz C. Santacruz-Tinoco C.E. Martínez-Miguel B. Maldonado-Hernández J. Cifuentes-González Y. Klünder-Klünder M. Garduño-Espinosa J. López-Martínez B. Parra-Ortega I. Efficacy and safety of vitamin D supplementation to prevent COVID-19 in frontline healthcare workers. A randomized clinical trial. Arch. Med. Res. 2022 53 4 423 430 10.1016/j.arcmed.2022.04.003 35487792
    [Google Scholar]
  65. Stambouli N. Driss A. Gargouri F. Bahrini K. Arfaoui B. Abid R. Taamallah K. Hannachi S. Boughariou S. Rebai A. Naas I. Ghanem M. Ammar H. Aichaouia C. Harrathi A. Yousfi M.A. Battikh R. Moussa M.B. Razgallah R. Ferjani M. Gharsallah H. COVID-19 prophylaxis with doxycycline and zinc in health care workers: A prospective, randomized, double-blind clinical trial. Int. J. Infect. Dis. 2022 122 553 558 10.1016/j.ijid.2022.06.016 35724828
    [Google Scholar]
  66. Delehedde C. Even L. Midoux P. Pichon C. Perche F. Intracellular routing and recognition of lipid-based mRNA nanoparticles. Pharmaceutics 2021 13 7 945 10.3390/pharmaceutics13070945 34202584
    [Google Scholar]
  67. Mulligan M.J. Lyke K.E. Kitchin N. Absalon J. Gurtman A. Lockhart S. Neuzil K. Raabe V. Bailey R. Swanson K.A. Li P. Koury K. Kalina W. Cooper D. Fontes-Garfias C. Shi P.Y. Türeci Ö. Tompkins K.R. Walsh E.E. Frenck R. Falsey A.R. Dormitzer P.R. Gruber W.C. Şahin U. Jansen K.U. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020 586 7830 589 593 10.1038/s41586‑020‑2639‑4 32785213
    [Google Scholar]
  68. Jackson L.A. Anderson E.J. Rouphael N.G. Roberts P.C. Makhene M. Coler R.N. McCullough M.P. Chappell J.D. Denison M.R. Stevens L.J. Pruijssers A.J. McDermott A. Flach B. Doria-Rose N.A. Corbett K.S. Morabito K.M. O’Dell S. Schmidt S.D. Swanson P.A. II Padilla M. Mascola J.R. Neuzil K.M. Bennett H. Sun W. Peters E. Makowski M. Albert J. Cross K. Buchanan W. Pikaart-Tautges R. Ledgerwood J.E. Graham B.S. Beigel J.H. An mRNA vaccine against SARS-CoV-2: Preliminary report. N. Engl. J. Med. 2020 383 20 1920 1931 10.1056/NEJMoa2022483 32663912
    [Google Scholar]
  69. Pardi N. Hogan M.J. Porter F.W. Weissman D. mRNA vaccines: A new era in vaccinology. Nat. Rev. Drug Discov. 2018 17 4 261 279 10.1038/nrd.2017.243 29326426
    [Google Scholar]
  70. Sandbrink J.B. Shattock R.J. RNA vaccines: A suitable platform for tackling emerging pandemics? Front. Immunol. 2020 11 608460 10.3389/fimmu.2020.608460 33414790
    [Google Scholar]
  71. Dolgin E. Ledford H. mRNA COVID vaccines saved lives and won a nobel: What’s next for the technology? Nature 2023 Epub ahead of print. 10.1038/d41586‑023‑03119‑x
    [Google Scholar]
  72. Chaudhary N. Weissman D. Whitehead K.A. mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. Nat. Rev. Drug Discov. 2021 20 11 817 838 10.1038/s41573‑021‑00283‑5 34433919
    [Google Scholar]
  73. Mulligan M.J. Lyke K.E. Kitchin N. Absalon J. Gurtman A. Lockhart S. Neuzil K. Raabe V. Bailey R. Swanson K.A. Li P. Koury K. Kalina W. Cooper D. Fontes-Garfias C. Shi P.Y. Türeci Ö. Tompkins K.R. Walsh E.E. Frenck R. Falsey A.R. Dormitzer P.R. Gruber W.C. Şahin U. Jansen K.U. Publisher correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2021 590 7844 E26 10.1038/s41586‑020‑03098‑3 33469216
    [Google Scholar]
  74. Kim J. Eygeris Y. Gupta M. Sahay G. Self-assembled mRNA vaccines. Adv. Drug Deliv. Rev. 2021 170 83 112 10.1016/j.addr.2020.12.014 33400957
    [Google Scholar]
  75. Wang Y. Zhang Z. Luo J. Han X. Wei Y. Wei X. mRNA vaccine: A potential therapeutic strategy. Mol. Cancer 2021 20 1 33 10.1186/s12943‑021‑01311‑z 33593376
    [Google Scholar]
  76. Blum J.S. Wearsch P.A. Cresswell P. Pathways of antigen processing. Annu. Rev. Immunol. 2013 31 1 443 473 10.1146/annurev‑immunol‑032712‑095910 23298205
    [Google Scholar]
  77. Sahin U. Muik A. Derhovanessian E. Vogler I. Kranz L.M. Vormehr M. Baum A. Pascal K. Quandt J. Maurus D. Brachtendorf S. Lörks V. Sikorski J. Hilker R. Becker D. Eller A.K. Grützner J. Boesler C. Rosenbaum C. Kühnle M.C. Luxemburger U. Kemmer-Brück A. Langer D. Bexon M. Bolte S. Karikó K. Palanche T. Fischer B. Schultz A. Shi P.Y. Fontes-Garfias C. Perez J.L. Swanson K.A. Loschko J. Scully I.L. Cutler M. Kalina W. Kyratsous C.A. Cooper D. Dormitzer P.R. Jansen K.U. Türeci Ö. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020 586 7830 594 599 10.1038/s41586‑020‑2814‑7 32998157
    [Google Scholar]
  78. Sainz B. Jr Mossel E.C. Peters C.J. Garry R.F. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 2004 329 1 11 17 10.1016/j.virol.2004.08.011 15476870
    [Google Scholar]
  79. Chen S. Guan F. Candotti F. Benlagha K. Camara N.O.S. Herrada A.A. James L.K. Lei J. Miller H. Kubo M. Ning Q. Liu C. The role of B cells in COVID-19 infection and vaccination. Front. Immunol. 2022 13 988536 10.3389/fimmu.2022.988536 36110861
    [Google Scholar]
  80. Bai J. Chiba A. Murayama G. Kuga T. Yahagi Y. Tabe Y. Tamura N. Miyake S. Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory. Sci. Rep. 2022 12 1 20376 10.1038/s41598‑022‑24938‑4 36437407
    [Google Scholar]
  81. Pape K.A. Dileepan T. Kabage A.J. Kozysa D. Batres R. Evert C. Matson M. Lopez S. Krueger P.D. Graiziger C. Vaughn B.P. Shmidt E. Rhein J. Schacker T.W. Khoruts A. Jenkins M.K. High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines. Cell Rep. 2021 37 2 109823 10.1016/j.celrep.2021.109823 34610291
    [Google Scholar]
  82. Xie C. Yao R. Xia X. The advances of adjuvants in mRNA vaccines. NPJ Vaccines 2023 8 1 162 10.1038/s41541‑023‑00760‑5 37884526
    [Google Scholar]
  83. Pulendran B. S Arunachalam P. O’Hagan D.T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 2021 20 6 454 475 10.1038/s41573‑021‑00163‑y 33824489
    [Google Scholar]
  84. Kobiyama K. Ishii K.J. Making innate sense of mRNA vaccine adjuvanticity. Nat. Immunol. 2022 23 4 474 476 10.1038/s41590‑022‑01168‑4 35354958
    [Google Scholar]
  85. Alameh M.G. Tombácz I. Bettini E. Lederer K. Ndeupen S. Sittplangkoon C. Wilmore J.R. Gaudette B.T. Soliman O.Y. Pine M. Hicks P. Manzoni T.B. Knox J.J. Johnson J.L. Laczkó D. Muramatsu H. Davis B. Meng W. Rosenfeld A.M. Strohmeier S. Lin P.J.C. Mui B.L. Tam Y.K. Karikó K. Jacquet A. Krammer F. Bates P. Cancro M.P. Weissman D. Luning Prak E.T. Allman D. Igyártó B.Z. Locci M. Pardi N. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 2021 54 12 2877 2892.e7 10.1016/j.immuni.2021.11.001 34852217
    [Google Scholar]
  86. Karikó K. Buckstein M. Ni H. Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005 23 2 165 175 10.1016/j.immuni.2005.06.008 16111635
    [Google Scholar]
  87. Mendonça S.A. Lorincz R. Boucher P. Curiel D.T. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines 2021 6 1 97 10.1038/s41541‑021‑00356‑x 34354082
    [Google Scholar]
  88. Milosevic I. Revisiting the role of clathrin-mediated endoytosis in synaptic vesicle recycling. Front. Cell. Neurosci. 2018 12 27 10.3389/fncel.2018.00027 29467622
    [Google Scholar]
  89. Chavda V. Bezbaruah R. Valu D. Patel B. Kumar A. Prasad S. Kakoti B. Kaushik A. Jesawadawala M. Adenoviral vector-based vaccine platform for COVID-19: Current status. Vaccines 2023 11 2 432 10.3390/vaccines11020432 36851309
    [Google Scholar]
  90. Coughlan L. Kremer E.J. Shayakhmetov D.M. Adenovirus-based vaccines: A platform for pandemic preparedness against emerging viral pathogens. Mol. Ther. 2022 30 5 1822 1849 10.1016/j.ymthe.2022.01.034 35092844
    [Google Scholar]
  91. Awate S. Babiuk L.A. Mutwiri G. Mechanisms of action of adjuvants. Front. Immunol. 2013 4 114 10.3389/fimmu.2013.00114 23720661
    [Google Scholar]
  92. Keech C. Albert G. Cho I. Robertson A. Reed P. Neal S. Plested J.S. Zhu M. Cloney-Clark S. Zhou H. Smith G. Patel N. Frieman M.B. Haupt R.E. Logue J. McGrath M. Weston S. Piedra P.A. Desai C. Callahan K. Lewis M. Price-Abbott P. Formica N. Shinde V. Fries L. Lickliter J.D. Griffin P. Wilkinson B. Glenn G.M. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 2020 383 24 2320 2332 10.1056/NEJMoa2026920 32877576
    [Google Scholar]
  93. Stertman L. Palm A.K.E. Zarnegar B. Carow B. Lunderius Andersson C. Magnusson S.E. Carnrot C. Shinde V. Smith G. Glenn G. Fries L. Lövgren Bengtsson K. The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century. Hum. Vaccin. Immunother. 2023 19 1 2189885 10.1080/21645515.2023.2189885 37113023
    [Google Scholar]
  94. Baden L.R. El Sahly H.M. Essink B. Follmann D. Hachigian G. Strout C. Overcash J.S. Doblecki-Lewis S. Whitaker J.A. Anderson E.J. Neuzil K. Corey L. Priddy F. Tomassini J.E. Brown M. Girard B. Stolman D. Urdaneta V. Wang X. Deng W. Zhou H. Dixit A. Das R. Miller J.M. Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases. Nat. Commun. 2024 15 1 7469 10.1038/s41467‑024‑50376‑z 39209823
    [Google Scholar]
  95. Mao Hu A.S. Feng Y. Patricia C. Safety of monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 vaccines in US children aged 6 months to 17 years. Medrxiv 2023
    [Google Scholar]
  96. Zeng B. Gao L. Zhou Q. Yu K. Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis. BMC Med. 2022 20 1 200 10.1186/s12916‑022‑02397‑y 35606843
    [Google Scholar]
  97. Firouzabadi N. Ghasemiyeh P. Moradishooli F. Mohammadi-Samani S. Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. Int. Immunopharmacol. 2023 117 109968 10.1016/j.intimp.2023.109968 37012880
    [Google Scholar]
  98. Chen Z. Zheng W. Wu Q. Chen X. Peng C. Tian Y. Sun R. Dong J. Wang M. Zhou X. Zhao Z. Zhong G. Yan X. Liu N. Hao F. Zhao S. Zhuang T. Yang J. Azman A.S. Yu H. Global diversity of policy, coverage, and demand of COVID-19 vaccines: A descriptive study. BMC Med. 2022 20 1 130 10.1186/s12916‑022‑02333‑0 35369871
    [Google Scholar]
  99. Li L. Zhang W. Hu Y. Tong X. Zheng S. Yang J. Kong Y. Ren L. Wei Q. Mei H. Hu C. Tao C. Yang R. Wang J. Yu Y. Guo Y. Wu X. Xu Z. Zeng L. Xiong N. Chen L. Wang J. Man N. Liu Y. Xu H. Deng E. Zhang X. Li C. Wang C. Su S. Zhang L. Wang J. Wu Y. Liu Z. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA 2020 324 5 460 470 10.1001/jama.2020.10044 32492084
    [Google Scholar]
  100. Eckhardt C.M. Cummings M.J. Rajagopalan K.N. Borden S. Bitan Z.C. Wolf A. Kantor A. Briese T. Meyer B.J. Jacobson S.D. Scotto D. Mishra N. Philip N.M. Stotler B.A. Schwartz J. Shaz B. Spitalnik S.L. Eisenberger A. Hod E.A. Justman J. Cheung K. Lipkin W.I. O’Donnell M.R. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2020 21 1 499 10.1186/s13063‑020‑04422‑y 32513308
    [Google Scholar]
  101. Lin Q. Li J. Wang Y. Zang J. Design, synthesis, and biological evaluation of novel ruxolitinib and baricitinib analogues for potential use against COVID‐19. Chem. Biol. Drug Des. 2023 101 3 760 771 10.1111/cbdd.14179 36366971
    [Google Scholar]
  102. Dallan B. Proietto D. De Laurentis M. Gallerani E. Martino M. Ghisellini S. Zurlo A. Volpato S. Govoni B. Borghesi M. Albanese V. Appay V. Bonnini S. Llewellyn-Lacey S. Pacifico S. Grumiro L. Brandolini M. Semprini S. Sambri V. Ladell K. Parry H.M. Moss P.A.H. Price D.A. Barbieri E. Bernardi T. Boni M. Dall’Olio L. De Laurentis M. Fiorini C. Fiorini M. Govoni M. Neri M. Palma F. Romagnoni F. Caputo A. Gavioli R. Nicoli F. Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19. Nature Aging 2024 4 8 1121 1136 10.1038/s43587‑024‑00644‑w 38918602
    [Google Scholar]
  103. Corbett K.S. Edwards D.K. Leist S.R. Abiona O.M. Boyoglu-Barnum S. Gillespie R.A. Himansu S. Schäfer A. Ziwawo C.T. DiPiazza A.T. Dinnon K.H. Elbashir S.M. Shaw C.A. Woods A. Fritch E.J. Martinez D.R. Bock K.W. Minai M. Nagata B.M. Hutchinson G.B. Wu K. Henry C. Bahl K. Garcia-Dominguez D. Ma L. Renzi I. Kong W.P. Schmidt S.D. Wang L. Zhang Y. Phung E. Chang L.A. Loomis R.J. Altaras N.E. Narayanan E. Metkar M. Presnyak V. Liu C. Louder M.K. Shi W. Leung K. Yang E.S. West A. Gully K.L. Stevens L.J. Wang N. Wrapp D. Doria-Rose N.A. Stewart-Jones G. Bennett H. Alvarado G.S. Nason M.C. Ruckwardt T.J. McLellan J.S. Denison M.R. Chappell J.D. Moore I.N. Morabito K.M. Mascola J.R. Baric R.S. Carfi A. Graham B.S. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020 586 7830 567 571 10.1038/s41586‑020‑2622‑0 32756549
    [Google Scholar]
  104. Kyaw M.H. Spinardi J. Zhang L. Oh H.M.L. Srivastava A. Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines. Hum. Vaccin. Immunother. 2023 19 1 2165856 10.1080/21645515.2023.2165856 36727201
    [Google Scholar]
  105. Rahimi F. Darvishi M. Bezmin Abadi A.T. ‘The end’ – Or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants. Future Virol. 2023 18 13 823 825 10.2217/fvl‑2023‑0150 37736262
    [Google Scholar]
  106. Zhang L. Kempf A. Nehlmeier I. Cossmann A. Dopfer-Jablonka A. Stankov M.V. Schulz S.R. Jäck H.M. Behrens G.M.N. Pöhlmann S. Hoffmann M. Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3. Lancet Infect. Dis. 2023 23 10 e391 e392 10.1016/S1473‑3099(23)00547‑9 37716358
    [Google Scholar]
  107. Yang S. Yu Y. Xu Y. Jian F. Song W. Yisimayi A. Wang P. Wang J. Liu J. Yu L. Niu X. Wang J. Wang Y. Shao F. Jin R. Wang Y. Cao Y. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 2024 24 2 e70 e72 10.1016/S1473‑3099(23)00744‑2 38109919
    [Google Scholar]
  108. Venturas J.P. HIV and COVID-19 disease. Semin. Respir. Crit. Care Med. 2023 44 1 035 049 10.1055/s‑0042‑1758852 36646084
    [Google Scholar]
  109. Ko S.H. Radecki P. Belinky F. Bhiman J.N. Meiring S. Kleynhans J. Amoako D. Guerra Canedo V. Lucas M. Kekana D. Martinson N. Lebina L. Everatt J. Tempia S. Bylund T. Rawi R. Kwong P.D. Wolter N. von Gottberg A. Cohen C. Boritz E.A. Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection. Nat. Commun. 2024 15 1 7240 10.1038/s41467‑024‑51539‑8 39174553
    [Google Scholar]
  110. Kouhpayeh H. Ansari H. HIV infection and increased risk of COVID-19 mortality: A meta-analysis. Eur. J. Transl. Myol. 2021 31 4 10107 10.4081/ejtm.2021.10107 34962366
    [Google Scholar]
  111. Kanagala S.G. Dholiya H. Jhajj P. Patel M.A. Gupta V. Gupta S. Wu S. Jain R. Remdesivir-induced Bradycardia. South. Med. J. 2023 116 3 317 320 10.14423/SMJ.0000000000001519 36863055
    [Google Scholar]
  112. Gunaydin-Akyildiz A. Aksoy N. Boran T. Ilhan E.N. Ozhan G. Favipiravir induces oxidative stress and genotoxicity in cardiac and skin cells. Toxicol. Lett. 2022 371 9 16 10.1016/j.toxlet.2022.09.011 36152797
    [Google Scholar]
  113. Chouchana L. Boujaafar S. Gana I. Preta L.H. Regard L. Legendre P. Azoulay C. Canouï E. Zerbit J. Carlier N. Terrier B. Kernéis S. Batista R. Treluyer J.M. Zheng Y. Benaboud S. Plasma concentrations and safety of Lopinavir/Ritonavir in COVID-19 patients. Ther. Drug Monit. 2021 43 1 131 135 10.1097/FTD.0000000000000838 33230045
    [Google Scholar]
  114. Batteux B. Bodeau S. Gras-Champel V. Liabeuf S. Lanoix J.P. Schmit J.L. Andréjak C. Zerbib Y. Haye G. Masmoudi K. Lemaire-Hurtel A.S. Bennis Y. Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID‐19. Br. J. Clin. Pharmacol. 2021 87 3 1547 1553 10.1111/bcp.14489 32692462
    [Google Scholar]
  115. Doyno C. Sobieraj D.M. Baker W.L. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clin. Toxicol. (Phila.) 2021 59 1 12 23 10.1080/15563650.2020.1817479 32960100
    [Google Scholar]
  116. Law M.F. Ho R. Law K.W.T. Cheung C.K.M. Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. World J. Hepatol. 2021 13 12 1850 1874 10.4254/wjh.v13.i12.1850 35069994
    [Google Scholar]
  117. Almasi S. Rashidi A. Kachuee M.A. Shirazi B.M. Izadi S. Ghaffarpour S. Azimi M. Naghizadeh M.M. Makiani M.J. Ranjbar M. Goudarzi M. Rahimian N. Ghazanfari T. Effect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19. Int. Immunopharmacol. 2023 122 110565 10.1016/j.intimp.2023.110565 37454635
    [Google Scholar]
  118. Reid N.K. Joyner K.R. Lewis-Wolfson T.D. Baricitinib versus Tocilizumab for the treatment of moderate to severe COVID-19. Ann. Pharmacother. 2023 57 7 769 775 10.1177/10600280221133376 36314277
    [Google Scholar]
  119. Karolyi M. Gruebl A. Omid S. Saak M. Pawelka E. Hoepler W. Kelani H. Kuran A. Laferl H. Ott C. Pereyra D. Santol J. Seitz T. Traugott M. Assinger A. Wenisch C. Zoufaly A. Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: Results from a real-world cohort. Infection 2023 51 4 851 858 10.1007/s15010‑022‑01915‑7 36083403
    [Google Scholar]
  120. Vermeire S. Danese S. Zhou W. Ilo D. Klaff J. Levy G. Yao X. Chen S. Sanchez Gonzalez Y. Hébuterne X. Lindsay J.O. Higgins P.D.R. Cao Q. Nakase H. Colombel J.F. Loftus E.V. Jr Panaccione R. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): Overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. Lancet Gastroenterol. Hepatol. 2023 8 11 976 989 10.1016/S2468‑1253(23)00208‑X 37683686
    [Google Scholar]
  121. Rein L. Calero K. Shah R. Ojielo C. Hudock K.M. Lodhi S. Sadaka F. Bellam S. Palma C. Hager D.N. Daniel J. Schaub R. O’Hayer K. Theodoropoulos N.M. Randomized phase 3 trial of Ruxolitinib for COVID-19–Associated acute respiratory distress syndrome. Crit. Care Med. 2022 50 12 1701 1713 10.1097/CCM.0000000000005682 36226977
    [Google Scholar]
  122. Herman G.A. O’Brien M.P. Forleo-Neto E. Sarkar N. Isa F. Hou P. Chan K.C. Bar K.J. Barnabas R.V. Barouch D.H. Cohen M.S. Hurt C.B. Burwen D.R. Marovich M.A. Musser B.J. Davis J.D. Turner K.C. Mahmood A. Hooper A.T. Hamilton J.D. Parrino J. Subramaniam D. Baum A. Kyratsous C.A. DiCioccio A.T. Stahl N. Braunstein N. Yancopoulos G.D. Weinreich D.M. Chani A. Adepoju A. Mahmood A. Mortagy A. Dupljak A. Baum A. Brown A. Froment A. Hooper A. Margiotta A. Bombardier A. Islam A. Smith A. Dhillon A. McMillian A. Breazna A. Aslam A. Carpentino B. Kowal B. Siliverstein B. Horel B. Zhu B. Musser B. Bush B. Head B. Snow B. Zhu B. Debray C. Phillips C. Simiele C. Lee C. Nienstedt C. Trbovic C. Chan C.K-C. Elliott C. Fish C. Ni C. Polidori C. Enciso C. Caira C. Powell C. Kyratsous C.A. Baum C. McDonald C. Leigh C. Pan C. Wolken D. Manganello D. Liu D. Stein D. Weinreich D.M. Hassan D. Gulabani D. Fix D. Leonard D. Sarda D. Bonhomme D. Kennedy D. Darcy D. Barron D. Hughes D. Rofail D. Kaur D. Ramesh D. Bianco D. Cohen D. Forleo-Neto E. Jean-Baptiste E. Bukhari E. Doyle E. Bucknam E. Labriola-Tomkins E. Nanna E. Huffman O’Keefe E. Gasparino E. Fung E. Isa F. To F-Y. Herman G. Yancopoulos G.D. Bellingham G. Sumner G. Moggan G. Power G. Zeng H. Mariveles H. Gonzalez H. Kang H. Noor H. Minns I. Heirman I. Peszek I. Donohue J. Rusconi J. Austin J. Parrino J. Yo J. McDonnell J. Hamilton J.D. Boarder J. Wei J. Yu J. Malia J. Tucciarone J. Tyler-Gale J. Davis J.D. Strein J. Cohen J. Meyer J. Ursino J. Im J. Tramaglini J. Wolken J. Potter K. Scacalossi K. Naidu K. Browning K. Rutkowski K. Yau K. Woloshin K. Lewis-Amezcua K. Turner K. Dornheim K. Chiu K. Mohan K. McGuire K. Macci K. Ringleben K. Mohammadi K. Foster K. Knighton L. Lipsich L. Darling L. Boersma L. Cowen L. Hersh L. Jackson L. Purcell L. Sherpinsky L. Lai L. Faria L. Geissler L. Boppert L. Fiske L. Dickens M. Mancini M. Leigh M.C. O’Brien M.P. Batchelder M. Klinger M. Partridge M. Tarabocchia M. Wong M. Rodriguez M. Albizem M. O’Byrne M. Braunstein N. Sarkar N. Stahl N. Deitz N. Memblatt N. Shah N. Kumar N. Herrera O. Adedoyin O. Yellin O. Snodgrass P. Floody P. D’Ambrosio P. Gao P.X. Hou P. Hearld P. Li Q. Kitchenoff R. Ali R. Iyer R. Chava R. Alaj R. Pedraza R. Hamlin R. Hosain R. Gorawala R. White R. Yu R. Fogarty R. Dass S.B. Bollini S. Ganguly S. DeCicco S. Patel S. Cassimaty S. Somersan-Karakaya S. McCarthy S. Henkel S. Ali S. Geila Shapiro S. Kim S. Nossoughi S. Bisulco S. Elkin S. Long S. Sivapalasingam S. Irvin S. Wilt S. Min T. Constant T. Devins T. DiCioccio T. Norton T. Bernardo T. Chuang T-C. Wei V.J. Nuce V. Battini V. Caldwell W. Gao X. Chen X. Tian Y. Khan Y. Zhao Y. Kim Y. Dye B. Hurt C.B. Burwen D.R. Barouch D.H. Burns D. Brown E. Bar K.J. Marovich M. Clement M. Cohen M.S. Sista N. Barnabas R.V. Zwerski S. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: A randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 2022 22 10 1444 1454 10.1016/S1473‑3099(22)00416‑9 35803290
    [Google Scholar]
  123. Zhao Y. Wang H. Zhang Q. Hu Y. Xu Y. Liu W. Evaluation of adverse events of Bamlanivimab, Bamlanivimab/Etesevimab used for COVID-19 based on FAERS database. Expert Opin. Drug Saf. 2023 22 4 331 338 10.1080/14740338.2023.2130888 36178050
    [Google Scholar]
  124. Gao Q. Yin X. Tan B. Wang J. Chen J. Zhao B. Yang Q. Li Z. Drug-induced liver injury following the use of tocilizumab or Sarilumab in patients with coronavirus disease 2019. BMC Infect. Dis. 2022 22 1 929 10.1186/s12879‑022‑07896‑0 36503381
    [Google Scholar]
  125. Kyriazopoulou E. Panagopoulos P. Metallidis S. Dalekos G.N. Poulakou G. Gatselis N. Karakike E. Saridaki M. Loli G. Stefos A. Prasianaki D. Georgiadou S. Tsachouridou O. Petrakis V. Tsiakos K. Kosmidou M. Lygoura V. Dareioti M. Milionis H. Papanikolaou I.C. Akinosoglou K. Myrodia D.M. Gravvani A. Stamou A. Gkavogianni T. Katrini K. Marantos T. Trontzas I.P. Syrigos K. Chatzis L. Chatzis S. Vechlidis N. Avgoustou C. Chalvatzis S. Kyprianou M. van der Meer J.W.M. Eugen-Olsen J. Netea M.G. Giamarellos-Bourboulis E.J. An open label trial of anakinra to prevent respiratory failure in COVID-19. eLife 2021 10 e66125 10.7554/eLife.66125 33682678
    [Google Scholar]
  126. Grundmann A. Wu C.H. Hardwick M. Baillie J.K. Openshaw P.J.M. Semple M.G. Böhning D. Pett S. Michael B.D. Thomas R.H. Galea I. Fewer COVID‐19 neurological complications with Dexamethasone and Remdesivir. Ann. Neurol. 2023 93 1 88 102 10.1002/ana.26536 36261315
    [Google Scholar]
/content/journals/chr/10.2174/011570162X338375250414114957
Loading
Navigating the COVID-19 Treatment Landscape: Efficacy and Side-Effects of Current Therapies against SARS-CoV-2
Bentham Science Publishers ; https://doi.org/10.2174/011570162X338375250414114957
/content/journals/chr/10.2174/011570162X338375250414114957
/content/journals/chr/10.2174/011570162X338375250414114957
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Immunotherapies ; SARS-CoV-2 ; mRNA vaccines ; HIV ; antivirals ; COVID-19

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test